A Different Tune: Patient-Centered Treatment of Psoriasis and Psoriatic Arthritis

Leading dermatology/rheumatology faculty and a patient presenter led attendees through changes in the psoriasis/psoriatic arthritis landscape via an interactive activity featuring TED Talk-style presentations, patient storytelling, and a discussion. The presenters focused on advances in the clinical areas of psoriasis and psoriatic arthritis, as well as how these advances introduce changes in the lives of people suffering from psoriatic disease, the increased complexity of care, and changes in routine clinical practice due to new, increasingly efficacious treatments. The activity concluded with key teaching points and a question and answer session.

Date: February 16, 2018

Venue: Sheraton San Diego Hotel & Marina, San Diego, California

Review activity content under the Materials button (below).



Lakshi Aldredge, MSN, ANP-BC

Nurse Practitioner,
VA Portland Healthcare System
Portland, Oregon

April W. Armstrong, MD, MPH

Associate Dean for Clinical Research,
Associate Professor of Dermatology,
Director of Clinical Research,
Southern California Clinical and Translational Science Institute
Director of Clinical Trials and Outcomes Research,
Director of Psoriasis Program,
Department of Dermatology
Keck School of Medicine
University of Southern California
Los Angeles, California

Rebecca Muntean, MD, ND, FACR

Clinical Rheumatologist,
Providence Health & Services
University of Washington WWAMI Regional Medical Education
Providence Spokane Internal Medicine
Premier Clinical Research
Providence Health & Services
Spokane, Washington
University of Southern California
Los Angeles, California

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

Discuss new and emerging treatments for psoriasis and psoriatic arthritis.

Screen patients with psoriasis for psoriatic arthritis at each visit.

Reflect on recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) for treatment of psoriatic arthritis.

Utilize practical treatment considerations for patients with challenging comorbidities.

Coordinate care with rheumatology providers and other healthcare providers who treat patients with psoriasis and psoriatic arthritis.

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and Interstate Postgraduate Medical Association must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Jessica Porucznik and Marianna Shershneva, MD, PhD
  • Planner: Fred Martin, MD
  • Planner: Dan Sommer
  • Presenter: Lisa Lambert

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Lakshi Aldredge, MSN, ANP-BC: consultant and speaker for AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Novartis, Sanofi, and Regeneron
  • Presenter: April W. Armstrong, MD, MPH: consultant for Novartis, Sanofi, Regeneron, Pfizer Inc., Celgene Corporation, Modernizing Medicine, AbbVie Inc., Eli Lilly and Company, Merck, and Janssen Pharmaceutical Inc.; researcher and speaker for Eli Lilly and Company, AbbVie Inc., and Janssen Pharmaceutical Inc.
  • Planner: Rebecca Muntean MD, ND, FACR: speaker for Janssen Pharmaceutical Inc.

Activity Information

Target Audience
The target audience for this activity was nurse practitioners and physician assistants who specialize in dermatology.  Dermatologists and other clinicians who are members of the healthcare team providing care for patients with psoriasis may have benefited from participation in this educational activity.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designated this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interstate Postgraduate Medical Association is approved by the California Board of Registered Nursing, Provider Number 6971, for 1.5 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

This activity was approved for 1.25 contact hour(s) of continuing education (which includes 0.75 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 18013001. This activity was planned in accordance with AANP Accreditation Standards and Policies.

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

The content of this activity was independently peer reviewed by two reviewers and two patients with psoriasis and psoriatic arthritis. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity included reference to unlabeled or unapproved uses of drugs.

This activity is provided by Forefront Collaborative in collaboration with Interstate Postgraduate Medical Association.

Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Not Enrolled
This course is currently closed